Active Biotech AB

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

W0250B198
SEDOL

B28DX83
CIK

N/A

www.activebiotech.com
LEI:
FIGI: BBG000BHG2Q9
ACTI

Active Biotech AB
GICS: - · Sector: Health Care · Sub-Sector: Health Care
NAME
Active Biotech AB
ISIN
SE0001137985
TICKER
ACTI
MIC
XSTO
REUTERS
ACTI.ST
BLOOMBERG
ACTI SS
EN 728x90
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
In this section you will find transaction histories for short sales.
ai
NALIZER
Short sellers are obliged to report when building up positions from 0.50% and when reducing positions up to 0.50%. If there are open positions >= 0.50% in the reporting registers, these are shown in the following overview.
Five Short sale positions >= 0.50% are currently registered as reportable-relevant
Date Position Holder Position # Action
12.02.2021 GUEVOURA FUND 0,50% 18
29.05.2015 OrbiMed Advisors LLC 0,50% 21
03.03.2015 GSA Capital Partners LLP 0,50% 8
29.01.2015 Friends Provident International Limited 0,50% 2
07.03.2013 Oxford Asset Management 0,50% 4
The overview shows all positions and their last reported status. Please note that when reducing positions, falling below the 0.50% limit means that the mandatory reporting obligations no longer have to be applied. As a rule, it can be assumed that the positions have been completely reduced following a longer period of inactivity. Positions < 0.50% are therefore only of limited significance.
Date Position Holder Position # Action
12.02.2021 GUEVOURA FUND 0,50% 18
29.05.2015 OrbiMed Advisors LLC 0,50% 21
03.03.2015 GSA Capital Partners LLP 0,50% 8
29.01.2015 Friends Provident International Limited 0,50% 2
07.03.2013 Oxford Asset Management 0,50% 4
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements
The information provided in this area is compiled with care and prepared and processed in complex technical process steps. Quality assurance is an integral part of the methods and procedures used. A plausibility check is carried out to the extent that the source data allows. Before further use, especially in the course of any investment decisions, we recommend consulting at least one second independent source for validation.